This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
The common pharmacologic strategies used to treat gastroesophageal reflux disease (GERD) in the neonatal intensive care unit (NICU) include suppression of gastric acid with histamine-2 (H2) receptor antagonists and proton pump inhibitors (PPIs) and stimulation of gastrointestinal motility with dopamine receptor antagonists or motilin receptor agonists. These medications are primarily metabolized by hepatic cytochrome P450 (CYP) enzymes. Although frequently used, none of these drugs has strong evidence for efficacy in decreasing the complications of reflux in preterm infants or term neonates. In addition, a few well-conducted, masked, randomized studies that have accounted for maturational changes in their design have raised concerns about the safety of these medications in infants.
- Copyright © 2011 by the American Academy of Pediatrics
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.